Visão geral da empresa
A biopharmaceutical enterprise, Context Therapeutics Inc., focuses on the development of therapeutic products specifically designed for the treatment of solid tumors. This operational focus places the company firmly within the healthcare sector, specifically navigating the competitive and high-risk biotechnology industry. The entity currently maintains a market capitalization of $237.97M and employs a workforce of 15 individuals. These valuation metrics and employee figures indicate that Context Therapeutics operates as a small-cap, early-stage biotechnology firm with limited revenue generation at this stage of development. The absence of reported annual revenue in the available financial data further underscores the company's position as an R&D-intensive entity that relies on capital markets to fund its clinical pipeline rather than commercial product sales. Consequently, the company's scale is defined more by its potential pipeline value and market cap than by traditional operational revenue or profit margins.
Saúde financeira
The financial profile of Context Therapeutics Inc. reflects the typical characteristics of a pre-revenue biopharmaceutical company, with reported revenue (TTM) listed as N/A and a net income (TTM) of $-36,123,616. The significant gap between the reported zero revenue and the substantial negative net income reveals a cost structure dominated by research and development expenditures rather than cost of goods sold. EBITDA for the trailing twelve months stands at $-39,686,380, indicating that the company has not yet achieved operational profitability. Free cash flow is reported at $-19,126,216, which signifies a continuous burn rate that consumes the company's cash reserves to fund its scientific and clinical operations. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure that is consistent with a business model that has not yet generated commercial sales volume. Despite these negative earnings, the company holds $66.00M in cash against total debt of $112,064, resulting in a debt-to-equity ratio of 0.18. This balance sheet composition suggests a relatively conservative leverage position relative to the size of its cash holdings, though the absolute debt amount is non-negligible for a company with negative earnings. The current ratio stands at 8.52, which indicates a very strong short-term liquidity position, suggesting the company has ample current assets to cover its short-term liabilities without immediate distress. Return on Equity is -46.4% and Return on Assets is -29.8%, metrics that reveal management is currently deploying capital to generate losses rather than returns, a common scenario for biotech firms in the clinical development phase.
Avaliação de valorização
Valuation metrics for Context Therapeutics Inc. present a mixed picture due to the lack of positive earnings. The trailing P/E ratio is N/A, while the forward P/E is -5.60, implying that the market expects earnings to remain negative in the near term or that the current earnings trajectory does not yet reflect a turnaround. The price-to-book ratio is 3.94, indicating that the market values the company at a significant premium over its tangible book value, likely pricing in the potential future value of its clinical assets and intellectual property. The price-to-sales ratio is N/A, and the EV/EBITDA stands at -4.34, suggesting that traditional valuation multiples based on sales or earnings are not applicable for this pre-commercial entity. The stock's 52-week trading range has fluctuated between a low of $0.49 and a high of $3.62, providing a context for price volatility. The beta value of 1.83 indicates that the stock exhibits high price volatility relative to the broader market, moving significantly more than the average equity in the S&P 500. This high beta reflects the inherent risk associated with biotechnology investments where stock price is heavily influenced by clinical trial outcomes and regulatory milestones rather than stable cash flows.
Growth & Income
Growth metrics for Context Therapeutics Inc. are currently unavailable, with revenue growth (YoY) and earnings growth (YoY) both listed as N/A. Consequently, it is not possible to determine whether earnings are growing faster or slower than revenue, as the company has not yet established a baseline of commercial sales to measure growth against. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This financial policy indicates that the company reinvests all available earnings and cash flow back into the business to fund research and development rather than distributing income to shareholders. The overall growth and income profile for Context Therapeutics is characterized by a reliance on external capital to sustain operations while the company works toward commercializing its lead candidate, CTIM-76, rather than generating organic growth or shareholder distributions through dividends.